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Abstract: Photodynamic therapy (PDT) is an emerging treatment modality for various 
diseases, especially for dermatological conditions. Although the standard PDT protocol for 
the treatment of actinic keratoses in Europe has shown to be effective, treatment-associated 
pain is often observed in patients. Different modifications to this protocol attempted to 
decrease pain have been investigated. The decrease in fluence rate seems to be a promising 
solution. Moreover, it has been suggested that light fractionation significantly increases the 
efficacy of PDT. Based on a flexible light-emitting textile, the FLEXITHERALIGHT device 
specifically provides a fractionated illumination at a fluence rate more than six times lower 
than that of the standard protocol. In a recently completed clinical trial of PDT for the 
treatment of actinic keratosis, the non-inferiority of a protocol involving illumination with the 
FLEXITHERALIGHT device after a short incubation time and referred to as the 
FLEXITHERALIGHT protocol has been assessed compared to the standard protocol. In this 
paper, we propose a comparison of the two above mentioned 635 nm red light protocols with 
37 J/cm
2
 in the PDT treatment of actinic keratosis: the standard protocol and the 
FLEXITHERALIGHT one through a mathematical modeling, which slightly differs from the 
one we have already published. This comparison performed in terms of the local damage 
induced by the therapy demonstrates that the FLEXITHERALIGHT protocol with lower 
fluence rate, light fractionation and shorter incubation time is somewhat less efficient than the 
standard protocol. Nevertheless, from the clinical trial results, the FLEXITHERALIGHT 
protocol results in non-inferior response rates compared to the standard protocol. This finding 
raises the question of whether the PDT local damage achieved by the FLEXITHERALIGHT 
protocol (respectively, the standard protocol) is sufficient (respectively, excessive) to destroy 
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actinic keratosis cells… 
 
I. Introduction 
 
Photodynamic therapy (PDT) is a cancer treatment modality combining light of an 
appropriate wavelength, a nontoxic photosensitizer, and sufficient molecular oxygen to 
generate reactive oxygen species and destroy (pre-) malignant cells [1]. PDT using 5-
aminolevulinic acid (ALA) (ALA-PDT) and PDT using 5-aminolevulinic acid methyl ester 
(MAL) (MAL-PDT) have been widely used for dermatological applications in recent decades 
[2-8]. Topical administration of ALA or MAL induces the selective accumulation of the 
endogenous photosensitizer protoporphyrin IX (PpIX) within the target cells and subsequent 
light irradiation leads to the target destruction. ALA-PDT and MAL-PDT have in particular 
proven to be an efficient treatment modality for actinic keratoses (AK) [9,10]. 
 
Actinic keratoses are scaly or crusty lesions that develop on sun-exposed areas, such as the 
face, scalp, neck, arms… in response to prolonged exposure to ultraviolet radiation. Confined 
to the epidermis (the basement membrane is intact), AKs are carcinomas in situ and, in 
approximately 10% of patients, will progress to invasive squamous cell carcinomas (SCCs) 
[11]. In order to reduce the subsequent risk of developing SCCs, most clinicians routinely 
treat AKs. Treatment options include lesion-directed destructive therapies, such as 
cryotherapy and surgical procedures, for individual lesions and field-directed therapies, such 
as topical medications and PDT, for areas with multiple or subclinical AKs. Compared to the 
other treatment options, the main advantage of PDT is the non-invasive nature and the 
excellent cosmetic results of this method [4,12]. 
 
A variety of PDT protocols with different photosensitizers, photosensitizer incubation times, 
light sources, light fluence rates… have been used for the treatment of AKs [12]. MAL-PDT 
using 635 nm red light with a total light dose of 37 J/cm
2
, a fluence rate of 75 mW/cm
2
 and 
three hours of incubation time is a standard protocol, widely used in Europe for the treatment 
of actinic keratosis. This protocol has been reported to be an effective PDT treatment option 
for AK and to result in similar response rates and improved cosmetic outcomes compared 
with standard therapies [9]. However, with these light dose parameters, high pain scores have 
been demonstrated and concurrent use of cold air analgesia may be required to prevent 
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discomfort [13,14]. Alternative red light protocols with lower fluence rates, as effective as the 
standard protocol while being much better tolerated by patients, have been studied for the 
treatment of AK [15-17]. Furthermore, fractionated irradiation with alternating light and dark 
periods, intended to allow tissue re-oxygenation and photosensitizer re-synthesis during the 
dark periods, has been demonstrated to increase the efficiency of the PDT for AK treatment 
[18,19]. 
 
Developed in the framework of the French National Research Agency (ANR) Project 
FLEXITHERALIGHT (http://www.flexitheralight.com/), the FLEXITHERALIGHT device is 
composed of three adjacent light emitting textiles [20], which sequentially emit red light (635 
nm) at low fluence rate (12.3 mW/cm
2
) for one minute allowing a fractionated illumination (1 
minute light, 2 minutes dark). The illumination duration of 2.5 hours already programmed in 
the device enables a light dose of 37 J/cm
2
 to be delivered in contact with the textiles. 
Combining illumination with the FLEXITHERALIGHT device with 30 minutes of incubation 
time, the FLEXITHERALIGHT protocol is being investigated for the treatment of actinic 
keratoses by the FLEXITHERALIGHT project. A phase II clinical trial approved by the 
French National Agency for Medicines and Health Products Safety (ANSM) on 27 November 
2013 (registration number: 2013-A1096-39) and aiming to assess the non-inferiority of the 
FLEXITHERALIGHT protocol compared to the above mentioned standard 635 nm red light 
protocol for the treatment of actinic keratoses has just ended. 
 
Based on this research project, we propose in this paper to compare the efficiency of the 
standard 635 nm red light protocol (incubation time: three hours, irradiation type: continuous, 
light dose: 37 J/cm
2
, fluence rate: 75 mW/cm
2
, treatment duration: 493 s) to the one of the 
FLEXITHERALIGHT protocol involving lower fluence rate, light fractionation and lower 
incubation time (incubation time: 30 minutes, illumination type: fractionated with two 
minutes dark intervals every three minutes, light dose: 37 J/cm
2
, fluence rate: 12.3 mW/cm
2
, 
treatment duration: 9024 s) through a mathematical modeling. This mathematical modeling 
greatly inspired by our previous works [21] and involving an improved model for both the 
biological clearance of PpIX and the conversion of MAL into PpIX enables the local damage 
induced by the therapy to be estimated. 
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II. Clinical materials 
 
A. Presentation of the two red light protocols 
 
Two different 635 nm red light protocols with 37 J/cm
2
 were considered: the standard 
protocol using a three hours incubation period and a continuous irradiation with 75 mW/cm
2
 
fluence rate [16,22,23] and the FLEXITHERALIGHT protocol using a 30 minutes incubation 
period and a fractionated irradiation (1 minute light, 2 minutes dark) with 12.3 mW/cm
2
 
fluence rate (Table 1). 
 
The FLEXITHERALIGHT protocol has been proposed in the French National Research 
Agency (ANR) Project FLEXITHERALIGHT (http://www.flexitheralight.com/) in which our 
research unit is involved. This project aims to develop a biophotonic device based on a 
flexible light emitting textile [20] and dedicated to the treatment of dermatologic diseases and 
carcinoma. The major advantage of the flexible light emitting textile is its optimal 
conformation to the area to be treated, thus leading to a more homogeneous irradiation than 
that delivered by the standard rigid light sources (Figure 1). Consisted of three adjacent 
textiles of size 21.5 cm × 5 cm sequentially emitting red light as illustrated in Figure 1, the 
FLEXITHERALIGHT device enables to obtain a fractionated irradiation (1 minute light, 2 
minutes dark) with a fluence rate of 12.3 mW/cm
2
 leading to a light dose of 37 J/cm
2
 after 
9024 seconds of treatment (12.3 mW/cm
2
 × 9024 s × 1 minute light / (1 minute light + 2 
minutes dark)). Moreover, based on the comparative study of Wiegell et al. [24], the 
FLEXITHERALIGHT protocol involves a 30 minutes incubation with MAL under occlusive 
dressing and no MAL removal before irradiation (Table 1). 
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Figure 1: The three flexible light emitting textiles of the FLEXITHERALIGHT device are 
sequentially activated for one minute (http://www.flexitheralight.com/) 
 
Protocol name 
Incubation 
time 
Irradiation type Fluence rate 
Treatment 
duration 
Standard protocol 3 hours Continuous 75 mW/cm
2
 ~493 s 
FLEXITHERALIGHT 
protocol 
30 minutes Fractionated 12.3 mW/cm
2
 ~9024 s 
Table 1: Parameters for the two different 635 nm red light protocols with 37 J/cm
2
 
investigated in this paper
 
 
B. Clinical trial for the comparison of the two protocols 
 
A phase II clinical trial approved by the French National Agency for the Safety of Medicines 
and Health Products (ANSM) (authorization number: 2013-A01096-39) and the French Ethics 
Committee (CPP) (authorization number: CPP-03/051/2013) for the assessment of the non-
inferiority of the FLEXITHERALIGHT device compared to the standard photodynamic 
therapy for the treatment of actinic keratoses was initiated at the end of 2013 and was recently 
completed. 
 
This clinical trial was designed somewhat similarly to the study of Wiegell et al., which aims 
to compare standard MAL-PDT with daylight MAL-PDT [24]. First, the lesions of the 
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forehead and scalp were counted, photographed and divided into two symmetrical areas, 
which were then randomized to receive either PDT using the standard protocol or PDT using 
the FLEXITHERALIGHT protocol. After gentle surface preparation of the lesions and MAL 
application to the lesions, an occlusive dressing was placed for 30 minutes (respectively, 3 
hours) over the area randomly assigned to receive PDT using the FLEXITHERALIGHT 
protocol (respectively, the standard protocol). After 30 minutes, PDT using the 
FLEXITHERALIGHT protocol was applied to the corresponding assigned area without 
dressing removal. Once this treatment was completed, the treated area was protected with an 
aluminum foil and the area randomized to receive PDT using the standard protocol, was 
treated after dressing removal and lesions cleaning. 
 
At the end of the procedure, the patients indicated the level of pain experienced during PDT 
using the FLEXITHERALIGHT protocol and the one experienced during PDT using the 
standard protocol through a visual analogue scale (VAS) ranging 0 (no pain) to 10 (maximum 
pain). Pain was also assessed at 7 days after the treatment. 
 
The treatment response was evaluated at 3 and 6 months after the treatment based on 
comparisons with baseline photographs. 
 
III. Modeling method 
 
Except for the change made regarding the biological clearance of PpIX and the conversion of 
MAL into PpIX in section III.C.2, the modeling method is the same as in our previously 
validated work [21] and therefore only outlines are referred to in this paper without further 
discussion. 
 
A. Skin sample model 
 
Our simplified skin sample model consists of an epidermis section represented by a 150 μm 
thick parallelepiped and of an AK designed as an ellipsoid as already published in [21]. 
 
As AKs are confined to the epidermis, the ellipsoid is included in the parallelepiped in such a 
way that it lies on, but does not cross, the lower boundary of this parallelepiped which 
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represents the boundary between the epidermis and the dermis. To account for the thickening 
of the epidermis generally observed with AK, the thickness of the ellipsoid is set to 200 μm 
which leads, according to the curettage usually performed prior to PDT, to the skin sample 
model displayed on Figure 2. 
 
The epidermis and AK tissues are both assumed to be homogeneous and z

 is assumed to be 
the beam direction, which is also the depth direction of the skin sample model (Figure 2). 
 
 
Figure 2: Skin sample model 
 
B. Models for the two fluence rates 
 
In this paper, the spectral fluence rate for the standard protocol (respectively, for the 
FLEXITHERALIGHT protocol) was modeled as a 75 mW/cm
2
 (respectively, 12.3 mW/cm
2
) -
weighted Gaussian distribution with mean 635 nm and full width at half maximum (FWHM) 
of 19 nm as measured by Moseley et al. [25] from the Aktilite CL16 and CL128 (Galderma 
SA, Lausanne, Switzerland) (Figure 3). The total light dose of 37 J/cm
2
 is achieved with a 
treatment duration of 493 s using the standard protocol and 9024 s using the 
FLEXITHERALIGHT protocol (Table 1). 
 
For the standard protocol, after 3 h of incubation, a primary planar broad beam with a spectral 
fluence rate 0S  of 75 mW/cm
2
 (blue curve in Figure 3) is assumed to continuously 
perpendicularly irradiate, for 493 s, the surface of the skin sample model as illustrated in 
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Figure 2. For the FLEXITHERALIGHT protocol, the irradiation for 9024 s is assumed to be 
performed, after 30 minutes of incubation, using a spectral fluence rate 0S  of 12.3 mW/cm
2
 
(red curve in Figure 3) during the light periods and a fluence rate 0S  of 0 mW/cm
2
 during the 
dark periods. 
 
 
Figure 3: The 75 mW/cm
2
 and 12.3 mW/cm
2
 spectral fluence rates used for the standard and 
the FLEXITHERALIGHT protocols, respectively. 
 
C. Modeling of the PDT process 
 
Let the incubation start at time st 0  and let the light irradiation start at time starttt   (
3startt hours and 30startt  minutes for the standard protocol and the FLEXITHERALIGHT 
one, respectively) and last until endtt   ( stt startend 493  and stt startend 9024  for the 
standard protocol and the FLEXITHERALIGHT one, respectively). 
 
The model we developed consists of two steps that are iteratively repeated until the end of 
treatment: determination of the local fluence rate and updating of the PpIX absorption 
coefficient. 
 
1. Determination of the fluence rate 
 
Similarly to Farrell et al. [26], based on a PpIX concentration varying only with depth, z , 
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below the irradiated surface (Figure 3), the local total fluence rate at time t , depth z  and 
wavelength  , denoted by   ,, zt , is given by equation 1 [21,26,27]: 
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 
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Where: 
 The above defined 0S  (Figure 3) is the spectral fluence rate of the primary planar broad 
beam, 
 The total absorption coefficient, a , is the sum of the PpIX absorption coefficient, PpIXa , , 
and the actinic keratosis absorption coefficient, AKa , , 
 The total transport coefficient, t , is the sum of the total absorption coefficient, a , and 
the actinic keratosis reduced scattering coefficient [28], AKs, , 
 The effective attenuation coefficient, eff , is defined as ta 3 , 
 The two parameters, b  and P , depending on both the optical properties of the actinic 
keratosis and the boundary conditions at the actinic keratosis surface, are computed as 
described in [26]. 
 
2. Updating of the PpIX absorption coefficient 
 
During a PDT treatment, three processes affect the PpIX absorption coefficient: the biological 
clearance of PpIX, the conversion of ALA or MAL into PpIX and the PpIX photobleaching. 
 
In our previous work [21], the conversion of MAL into PpIX was modeled using an 
exponential growth function resulting in an controversial unlimited increase in time of the 
number of new PpIX molecules. In this paper, a more realistic model for the conversion of 
MAL into PpIX also taking into account the biological clearance of PpIX is defined based on 
clinical data from several studies while the photobleaching model is the same as in our 
previous work [21]. 
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In order to model the time evolution of the PpIX absorption coefficient when considering only 
the biological clearance of PpIX and the conversion of MAL into PpIX, we use the 
fluorescence data reported by Wiegell et al. [24]. These data that have been collected from 30 
patients during three hours of MAL application without light irradiation suggest a logistic 
growth in time of the number of PpIX molecules. Based on this suggestion that is supported 
by the fluorescence data measured from 23 actinic keratoses during 28 hours of MAL 
incubation by Angell-Petersen et al. [29], equation 2 can be established. The limited growth in 
the number of PpIX molecules assumed by equation 2 is also observed for the PpIX 
concentration data computed by Star et al. during four hours of MAL application at 0 and 0.2 
mm depth in the epidermis [30]. This latest data further demonstrates a depth-dependent 
shape of the logistic growth in time (the shape of the logistic growth depends on the depth in 
the epidermis). This dependence arising from the progressive skin penetration of MAL is 
taken into account in equation 2 through the limiting value of the logistic function as we 
deduced from the PpIX concentration data reported in [30]: 
 
 
  

tk
zL
ztM BCPpIX
exp1
,  (2) 
Where: 
  ztM BCPpIX ,  is the number of PpIX molecules present in an unit volume, UV , at time t  and 
depth z , when considering only the biological clearance of PpIX and the conversion of 
MAL into PpIX, 
  zL , k  and   are the limiting value, the steepness and the midpoint position of the 
logistic function representing the time evolution of  ztM BCPpIX , , respectively. 
 
Assuming a standard exponential depth decay with constant,  , for  zL , equation 2 becomes 
equation 3: 
 
   
  




tk
zL
ztM BCPpIX
exp1
exp0
,  (3) 
 
From equation 3, the variation in the number of PpIX molecules resulting from the biological 
clearance of PpIX and the conversion of MAL into PpIX during the time interval  dttt ;  
can be expressed as follows (equation 4): 
11 
 
     
   
     











tkdttk
zL
ztMzdttMztdM BCPpIX
BC
PpIX
BC
PpIX
exp1
1
exp1
1
exp0
,,,
 (4) 
 
Regarding the photobleaching process, based on our previous work [21], the number of PpIX 
molecules eliminated by photobleaching during the time interval  dttt ; , denoted by 
 ztdM PPpIX , , can be estimated using equation 5: 
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Where: 
  ztM PpIX ,  is the number of PpIX molecules present in an unit volume, UV , at time t  and 
depth z , 
   is the bimolecular rate constant for the reaction of singlet oxygen with PpIX, 
   is the Avogadro number (6.022×1023 /mol), 
  ~  is the singlet oxygen quantum yield (i.e. the number of singlet oxygen molecules 
generated for each photon of wavelength 
~
 absorbed by a PpIX molecule when the PDT 
process is not limited by the availability of oxygen), 
  is the Planck constant (6.626×1034 J×s), 
 c  is the speed of light (3×108 m/s). 
 
Combining equations 4 and 5 results in the following approximation equation for the number 
of PpIX molecules present at time dtt   (equation 6): 
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Based on the relationship  
 
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V
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U
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  where   PpIX  is the PpIX 
molar extinction coefficient for wavelength  , equation 6 can be rewritten in terms of the 
PpIX absorption coefficient giving the following updating formula for the PpIX absorption 
coefficient (equation 7): 
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(7) 
 
From equation 1, assuming a given distribution for the PpIX absorption coefficient at time 0, 
  


,,
,,0
zPpIXa
z , the local total fluence rate at time 0,   ,,0 z , can be calculated for any 
point of the skin model (Figure 2) and any wavelength of the spectrum. Equation 7 then 
enables the distribution for the PpIX absorption coefficient at time dt ,   


,,
,,
zPpIXa
zdt , to 
be computed. From this new distribution for the PpIX absorption coefficient, any local total 
fluence rate at time dt ,   ,, zdt , can be calculated using equation 1... Iterating equations 1 
and 7 therefore enables all the necessary PpIX absorption coefficients and local total fluence 
rates to be determined. 
 
3. Initialization 
We naturally assume that:  
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4. Parameters setting 
 
The optical properties for actinic keratosis mentioned in equation 1 are derived from the data 
reported in Garcia-Uribe et al. [31]. 
 
The parameters related to the photobleaching process (equation 5 and last term in equation 7) 
were assigned to the values used in our previous work [21] (Table 2). These values reported in 
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the literature have been empirically determined as stated in [21]. 
 
Parameters Value 
dt  1×10
-5
 s 
  5.3×10
9
 l/mol/s 

 ~  0.56 
Table 2: Specification of the model parameters from [21] 
 
Regarding the biological clearance of PpIX and the conversion of MAL into PpIX (second 
term in equation 7), four parameters remain to be specified:  0L , k  and   both introduced in 
equation 2 and   introduced in equation 3. 
 
From the fitting of equation 2 to the PpIX concentration data computed at zero depth in 
normal human epidermis by Star et al. [30],  0L  (  is the conversion factor between 
 ztM BCPpIX ,  and the corresponding PpIX concentration expressed in µg/g in [30]), k  and   
were estimated to be 3.43 AU, 2.93×10
-4
 /s and 1.01×10
4
 s, respectively. Computed from the 
PpIX concentration data at zero depth and the ratio between the PpIX concentration at 0.2 mm 
and at 0 mm both reported in [30], the PpIX concentration data at 0.2 mm depth were fitted to 
equation 2 leading to the values of 2.82 AU, 3.25×10
-4
 /s and 1.01×10
4
 s for  mmL 2.0 , k  
and  , respectively. Regarding k  and  , these values are close to the ones obtained using the 
PpIX concentration data computed at zero depth and are therefore consistent with the use of a 
single value as assumed in equation 2. 
 
Assuming   43.30 L  AU, /s10×2.93 -4k  and  /s10×1.01 4 , the fitting of equation 3 to 
the PpIX concentration data at 0.2 mm depth [30], enables the depth decay constant,  , to be 
deduced (Table 3). 
 
Finally,  0L  was determined combining equation 3 with the concentration at the skin surface 
 0z  of 11.8 pmol/ml obtained by Smits et al. [32] from 11 patients with AK incubated 
with 20% ALA for 3 hours (equation 8): 
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Parameters Value 
k  2.93×10
-4
 /s 
  1.01×104 s 
  0.89 /mm 
 0L  1.29×104 using  3μm10UV  
Table 3: Specification of the parameters for the biological clearance of PpIX and the 
conversion of MAL into PpIX 
 
D. Quantification of the PDT local damage 
 
The integral in the photobleaching term of equation 7 (last part of the right hand side) 
represents the number of singlet oxygen molecules generated during the time interval 
 dttt ;  in an unit volume, UV , located at depth z  in the skin sample model when the PpIX 
molecules, excited by absorption of photons, return to the ground state [21]. Therefore, the 
sum of this integral over the time intervals  dt;0 ,  dtdt 2; ,  dtdt 3;2 ,…,  ii tdtt ;  with 
dtitt starti   provides the total cumulative singlet oxygen molecules produced during the 
time interval  it;0 . Following several studies on PDT [26,33,34], this cumulative parameter 
enables the quantification of the PDT local damage, below-denoted as D , over time 
(equation 9). 
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IV. Results 
 
A. From the clinical trial 
 
The preliminary results obtained for the first 14 patients of the clinical trial [35] are 
summarized in Tables 4 and 5. From these results, PDT using the FLEXITHERALIGHT 
protocol is not inferior in terms of complete response rate when compared to PDT using the 
standard protocol (Table 4) while being more comfortable for patients (Table 5). 
 
Complete response rate At 3 months At 6 months 
Standard protocol 54.2% 64% 
FLEXITHERALIGHT 
protocol 
65.3% 71.7% 
Table 4: Estimation of the complete response rate for PDT using the standard protocol 
(second row) and for PDT using the FLEXITHERALIGHT protocol (third row) at 3 (second 
column) and 6 months (third column) from the results of the first 14 patients of the clinical 
trial [35]. 
 
Pain (0: no pain and 10: 
unbearable pain) 
At day 0 (treatment day) At day 7 
Standard protocol 
Mean: 5.2 (standard 
deviation: 2.8) 
Mean: 0.1 (standard 
deviation: 0.2) 
FLEXITHERALIGHT 
protocol 
Mean: 0.4 (standard 
deviation: 0.6) 
Mean: 0.1 (standard 
deviation: 0.2) 
Table 5: Estimation of the pain for PDT using the standard protocol (second row) and for 
PDT using the FLEXITHERALIGHT protocol (third row) at day 0 (second column) and day 
7 (third column) from the results of the first 14 patients of the clinical trial [35]. 
 
B. From the mathematical modeling study 
 
All the computations were performed using a Matlab™ program on a standard personal 
computer (Intel Xeon CPU E3-1240 V2 3.40 GHz–8Go of RAM–Windows 7 64 bits). 
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Figure 4 shows the evolution of the number of PpIX molecules as a function of time when 
using the standard and the FLEXITHERALIGHT protocols (equation 6). 
 
 
a 
 
b 
 
c 
 
d 
Figure 4: Evolution in time of the number of PpIX molecules when using the standard 
protocol (incubation time: three hours, irradiation type: continuous, light dose: 37 J/cm
2
, 
fluence rate: 75 mW/cm
2
, treatment duration: 493 s) (blue curves) and the 
FLEXITHERALIGHT one (incubation time: 30 minutes, irradiation type: fractionated with 
two minutes dark intervals every three minutes, light dose: 37 J/cm
2
, fluence rate: 12.3 
mW/cm
2
, treatment duration: 9024 s) (red curves) at 0 (a), 50 (b), 100 (c) and 150 (d) µm in 
depth in AK. 
 
From Figure 4, whatever the depth in AK, the number of PpIX molecules corresponding to 
the FLEXITHERALIGHT protocol continues to increase even after the beginning of 
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irradiation ( 30startt  minutes). This means that the number of PpIX molecules generated 
from the conversion of MAL is always higher than the number of PpIX molecules removed 
by either the biological clearance or the photobleaching of PpIX. Regarding the standard 
protocol, the irradiation leads to a mean percent drop of 32.04% in the number of PpIX 
molecules, that is close to the 27 percent drop computed from data reported in Wiegell et al. 
[24]. 
 
Whatever the protocol, an important number of PpIX molecules is still present at the end of 
the irradiation (Figure 4): for the standard protocol (respectively, for the 
FLEXITHERALIGHT protocol), this number is more than 7.59 (respectively, 9.59) times 
higher than the number of PpIX molecules present at the beginning of the incubation (i.e., at 
time 0t  s). 
 
The time evolution of the PDT local damage achieved when using the standard and the 
FLEXITHERALIGHT protocols is illustrated for different depths in AK in Figures 5 and 6. 
 
 
a 
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b 
Figure 5: Evolution in time of the PDT local damage achieved when using the standard 
protocol (incubation time: three hours, irradiation type: continuous, light dose: 37 J/cm
2
, 
fluence rate: 75 mW/cm
2
, treatment duration: 493 s) (blue curves) and the 
FLEXITHERALIGHT one (incubation time: 30 minutes, irradiation type: fractionated with 
two minutes dark intervals every three minutes, light dose: 37 J/cm
2
, fluence rate: 12.3 
mW/cm
2
, treatment duration: 9024 s) (red curves) at 50 (a) and 150 (b) µm in depth in AK. 
 
 
a 
 
b 
Figure 6: Time evolution of the PDT local damage as a function of the depth position in AK. 
Results are displayed for the standard protocol (incubation time: three hours, irradiation type: 
continuous, light dose: 37 J/cm
2
, fluence rate: 75 mW/cm
2
, treatment duration: 493 s) (a) and 
for the FLEXITHERALIGHT one (incubation time: 30 minutes, irradiation type: fractionated 
with two minutes dark intervals every three minutes, light dose: 37 J/cm
2
, fluence rate: 12.3 
mW/cm
2
, treatment duration: 9024 s) (b). 
 
As expected looking at the involved fluence rates and irradiation types, the PDT local damage 
produced using the standard protocol increases much faster than that produced using the 
FLEXITHERALIGHT protocol (Figure 5). From a linear regression of the PDT local damage 
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versus time performed for all depths in AK, the PDT local damage obtained using the 
standard protocol increases, on average, about 33.30 times faster than the one obtained using 
the FLEXITHERALIGHT protocol. 
 
Furthermore, as can be seen in Figures 5 and 6, whatever the depth position in AK, the PDT 
local damage achieved at the end of the treatment using the standard protocol is higher than 
the one achieved at the end of the treatment using the FLEXITHERALIGHT protocol. 
Ranging from 1.78 at 0 µm depth to 1.80 at 150 µm depth, the ratio of the PDT local damage 
achieved at the end of the treatment between using the standard protocol and using the 
FLEXITHERALIGHT protocol is a slightly increasing function of the depth position in AK. 
 
In addition, for both the protocols, an increasing impact of the depth in AK on the PDT local 
damage over time is observed in Figure 6. Moreover, the shape of the time course of the PDT 
local damage for the standard protocol tends to demonstrate a very slight logarithmic trend 
(Figure 6.a) while that for the FLEXITHERALIGHT protocol suggests an exponential trend 
(Figure 6.b). 
 
The local damages obtained at the end of the treatment using the standard protocol and the 
FLEXITHERALIGHT protocol are displayed according to depth in Figure 7. 
 
 
Figure 7: Depth evolution of the PDT local damage for the standard protocol (incubation 
time: three hours, illumination type: continuous, light dose: 37 J/cm
2
, fluence rate: 75 
mW/cm
2
, treatment duration: 493 s) (blue curves), and the FLEXITHERALIGHT protocol 
(incubation time: 30 minutes, illumination type: fractionated with two minutes dark intervals 
every three minutes, light dose: 37 J/cm
2
, fluence rate: 12.3 mW/cm
2
, treatment duration: 
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9024 s) (red curves). 
 
From Figure 7, the depth-related decrease rate in the PDT local damage obtained at the end of 
the treatment using the FLEXITHERALIGHT protocol seems to be similar to those obtained 
using the standard protocol. Nonetheless from a linear regression, the depth-related decrease 
rate for the FLEXITHERALIGHT protocol is around one-third smaller than that obtained 
using the standard protocol. 
 
V. Discussion 
 
In this paper, a comparison between the two following 635 nm red light protocols is 
performed for the PDT treatment of actinic keratosis using a mathematical modeling of the 
PDT process: 
 Protocol 1 with incubation time: three hours, irradiation type: continuous, light dose: 37 
J/cm
2
, fluence rate: 75 mW/cm
2
 
 Protocol 2 with incubation time: 30 minutes, irradiation type: fractionated with two 
minutes dark intervals every three minutes, light dose: 37 J/cm
2
, fluence rate: 12.3 
mW/cm
2
. 
 
The continuous 75 mW/cm
2
 red light protocol was considered due to its standardized use 
across Europe [16,22,23] while the choice of the fractionated 12.3 mW/cm
2
 red light protocol 
was motivated by the FLEXITHERALIGHT Project (http://www.flexitheralight.com/). This 
French National Research Agency Project focuses on the development of a biophotonic 
device based on a flexible light emitting textile enabling a fractionated irradiation with a 12.3 
mW/cm
2
 fluence rate for the PDT treatment of actinic keratosis. Based, on one hand, on the 
published results of some alternative red light protocols with lower fluence rates than the 
standard 75 mW/cm
2
 red light protocol [15-17], and on the other hand, on the tissue re-
oxygenation and photosensitizer re-synthesis during the dark periods of the fractionated 
irradiation, the FLEXITHERALIGHT protocol is expected to be at least as effective as the 
standard protocol while being much better tolerated by patients. The preliminary results from 
the phase II clinical trial (ANSM authorization number: 2013-A01096-39) live up to these 
expectations since they demonstrate that the FLEXITHERALIGHT protocol is not inferior in 
terms of complete response rate to the standard protocol and is much more comfortable for 
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patients. 
 
A 200-μm thick partial ellipsoid included into a 150-μm thick parallelepiped was used to 
model a post-curettage AK in epidermis and an iterative procedure alternating determination 
of the fluence rate and updating of the optical properties was derived from our previous work 
[21] to model the PDT process. The determination of the fluence rate involves solving the 
one-dimensional diffusion equation (equation 1) while the updating of the optical properties 
takes the biological clearance of PpIX, the conversion of MAL into PpIX and the PpIX 
photobleaching into account (equation 7). In this paper, the biological clearance of PpIX and 
the conversion of MAL into PpIX were described using a single logistic growth model 
(equations 2 and 3), that is, according to [24,29,30], a more realistic model compared to the 
two exponential models used in our previous work [21]. Regarding the photobleaching, we 
used the original model that we proposed in [21] (equation 5). This original photobleaching 
model involves the calculation of the number of singlet oxygen molecules generated over time 
assuming unlimited oxygen availability. This assumption that is made through the singlet 
oxygen quantum yield in equation 5, is deemed reasonable according to the thickness of the 
AK [36]. In fact, as mentioned in [21,36], the epidermis layer is almost exclusively supplied 
by diffused oxygen from the atmosphere, and the unlimited source of atmospheric oxygen 
allows unlimited oxygen availability in the skin sample model to be reasonably assumed. 
Finally, estimation of the cumulative number of singlet oxygen molecules produced during 
the treatment enables the quantification of the PDT local damage (equation 9). 
 
From the above-mentioned suitable assumption of unlimited oxygen availability, the 
fractionated irradiation aimed at allowing tissue re-oxygenation and photosensitizer re-
synthesis during the dark periods, is, in the proposed model, only taken into account for 
photosensitizer re-synthesis purposes. 
 
All the parameters involved in this model are set to published values obtained using PpIX and 
either normal human epidermis or AK [21]. 
 
Applying to the standard protocol and to the FLEXITHERALIGHT one, the model allows 
evaluation and comparison of their performance in terms of the PDT local damage. 
From the results, the higher fluence rate of the standard protocol compared to that of the 
FLEXITHERALIGHT protocol combined with the continuous irradiation type of the standard 
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protocol opposed to the fractionated irradiation of the FLEXITHERALIGHT protocol 
logically leads to a higher increase rate for the PDT local damage of the standard protocol — 
deduced to be more than 30 times higher than that for the PDT local damage of the 
FLEXITHERALIGHT protocol — (Figure 5). 
Furthermore, in spite of the identical light dose of 37 J/cm
2
 for the two protocols, using the 
well-known efficient standard protocol results in a PDT local damage at the end of the 
treatment of, on average, 1.79 times as high as that obtained using the FLEXITHERALIGHT 
protocol (Figures 5 and 6). 
However, the above-mentioned clinically-demonstrated non-inferiority in terms of complete 
response rate of the FLEXITHERALIGHT protocol versus the standard protocol, seems to 
highlight that the PDT local damage achieved using the FLEXITHERALIGHT protocol is 
sufficient to destroy any cancer cells and therefore that the parameters of the standard 
protocol should be revised accordingly. Thus, among the possible changes in parameters, 
reducing by half the treatment duration of the standard protocol (and therefore the light dose) 
may lead to a PDT local damage equivalent to the sufficient one obtained using the 
FLEXITHERALIGHT protocol (Figure 5). 
 
Regarding the time evolution of the PpIX molecules number in Figure 4, the beginning of the 
irradiation is clearly identifiable for the standard protocol with a more than 30 percent drop 
which is in close agreement with results from [24]. On the contrary, the steady growth curves 
observed for the FLEXITHERALIGHT protocol makes the identification of the beginning of 
the irradiation impossible: the 12.3 mW/cm
2
 fluence rate and the fractionated irradiation do 
not allow a photobleaching of the PpIX molecules important enough to outweigh the 
conversion of MAL into PpIX. Consideration also needs to be given to the important number 
of PpIX molecules still present at the end of the treatment for both the protocols (Figure 4). 
This important number tends to demonstrate that the incubation time of the two protocols — 
or the cream concentration in MAL —could be reduced [37]. 
 
Moreover, based on various studies on the impact of fluence rates on pain [15,16], a better 
tolerability in terms of pain is expected using the FLEXITHERALIGHT protocol. This 
expectation has been verified from the above-mentioned phase II clinical trial. 
 
Finally, these results confirmed by a first analysis of the clinical trial data emphasize the need 
to redefine standard protocols and better determine treatment parameters for a similar 
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efficiency but an improved tolerability and a more manageable clinical practice. 
 
VI. Conclusions 
 
In this paper, we have proposed to evaluate and compare two protocols: the standard protocol 
(wavelength: 635 nm, incubation time: three hours, illumination type: continuous, light dose: 
37 J/cm
2
, fluence rate: 75 mW/cm
2
) and an alternative one, the FLEXITHERALIGHT 
protocol (http://www.flexitheralight.com/) (wavelength: 635 nm, incubation time: 30 minutes, 
illumination type: fractionated with two minutes dark intervals every three minutes, light 
dose: 37 J/cm
2
, fluence rate: 12.3 mW/cm
2
). The evaluation tends to demonstrate that an 
optimization of the two protocols parameters and especially of the incubation times could lead 
to a similarly efficient and more suitable treatment while the comparison tends to prove a 
slightly better efficiency of the standard protocol in term of the PDT local damage. 
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